Wolters Kluwer Health
may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

PROVIDER ACCREDITATION

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 3.1 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223.

Your certificate is valid in all states. This activity has been assigned 3.1 pharmacology credits.

The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.

Pharmacologic therapy for female sexual dysfunction

General Purpose: To provide information on the research and recommendations for practice for treatment of FSD. Learning Objectives: After reading this article and taking the test, the learner should be able to: 1. Identify the classifications and prevalence of FSD. 2. Recognize the clinical evaluation process and the role of nonpharmacologic treatments. 3. Select pharmacologic therapies targeted for categories of FSD.

1. A linear model of the female sexual response cycle that is focused on the emotional and psychological factors of FSD, can be found in the

a. HRQol questionnaire.

b. Decreased Sexual Desire Screener.

c. DSM-5.

d. PLISSIT model.

2. Which statement concerning FSD is correct?

a. FSD is not reported by premenopausal American women.

b. FOD is the most prevalent category of FSD.

c. Comorbid health conditions may affect the presentation of FSD.

d. Researchers use standard methodology to document prevalence of FSD.